Press Releases and News

RedShiftBio to showcase successful studies with biopharma industry leaders at AAPS PharmSci 360 Read more>

Biopharm International interviews scientists with experience of Microfluidic Modulation Spectroscopy for a round-table on how complex protein studies demand dynamic techniques. Visit page 18 to see what Immunogen, Janssen, Elion Labs and the University of Delaware have to say. Read more>

American Pharmaceutical Review publishes article on MMS by Karan K. Shah Principal Development Associate Analytical and Pharmaceutical Sciences ImmunoGen, Inc. Read more>

RedShiftBio Strengthens Focus on Applications with New Hire Read more>

Spectroscopy North America publishes peer-reviewed paper on MMS from Brent Kendrick of Elion Labs, Eugene Ma and Libo Wang of RedShiftBio Read more>

RedShiftBio Expands Team to Support Launch of FlagShip AQS3™pro System for Protein Characterization Read more>

Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS3pro Read more>

Spectroscopy Europe highlights the launch of the AQS3pro Read more>

RedShiftBio Launches AQS3pro Protein Characterization System Read more>

RedShiftBio Announces Collaboration Trial Completion Read more>

Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer Read more >

RedShiftBio Inc. Completes $11.0 million Series C Financing Read more >

RedShiftBio™

RedShiftBio™ is an innovative provider of analytical instrumentation for the research, development and manufacturing of protein therapeutic drugs.

Read More

Learn More

MMS For Protein Therapeutic Drug Analysis

Enhanced Protein Structural Characterization using MMS

Contact Us

RedShift BioAnalytics Inc.

131 Middlesex Turnpike
Burlington, MA 01803

T: 781.345.7300
F: 781-345-7301
E: info@redshiftbio.com

RedShift™, RedShiftBio™,  See Change™, and AQS3™ are trademarks of RedShift BioAnalytics, Inc.